Compound Evidence File
#EC-2026-0573
Tesamorelin
Filed under Peptides. The bureau holds 325 laboratory returns for this compound from 59 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
59 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 10.0 | 10.0 | 28 Nov 2025 | 10 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 10.0 | 10.0 | 9 May 2026 | 1 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Apr 2026 | 2 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 20 Nov 2025 | 16 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 10.0 | 10.0 | 20 Dec 2025 | 13 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 10.0 | 10.0 | 12 May 2026 | 8 Aug 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 4 Apr 2026 | 7 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Jul 2026 | 5 Aug 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 25 Feb 2026 | 24 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 13 May 2026 | 17 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 8 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 6 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 1 Nov 2025 | 9 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 10.0 | 25 Apr 2026 | 5 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Jan 2026 | 17 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Jun 2026 | 12 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 23 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jun 2026 | 7 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 9.9 | 14 Apr 2026 | 19 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 28 Jan 2026 | 2 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Apr 2026 | 15 Jun 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 9.2 | 7.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 9.0 | 7.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.9 | 6.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | A | 3 | 8.3 | 6.4 | 10.0 | 9 Oct 2025 | 26 Jan 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.2 | 7.1 | 9.1 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.1 | 8.0 | 8.2 | 24 May 2026 | 24 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | B | 11 | 7.8 | 5.3 | 10.0 | 30 Jan 2026 | 21 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | D | 7 | 7.8 | 3.3 | 10.0 | 9 Sep 2025 | 17 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | D | 8 | 7.2 | 3.4 | 10.0 | 4 Nov 2025 | 21 May 2026 |
| UtherCASE #VI-2026-0902 | A | 4 | 7.1 | 6.4 | 7.8 | 24 Jul 2025 | 19 May 2026 |
| NexaphCASE #VI-2026-0944 | D | 21 | 7.0 | 3.2 | 9.7 | 29 Jun 2025 | 24 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | D | 10 | 6.7 | 3.0 | 10.0 | 9 Sep 2025 | 24 May 2026 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 6.7 | 6.7 | 6.7 | 25 May 2026 | 25 May 2026 |
| HXNetCASE #VI-2026-0061 | D | 11 | 6.3 | 3.5 | 8.0 | 24 Jul 2025 | 24 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | E | 28 | 6.2 | 1.0 | 10.0 | 4 Aug 2025 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | B | 5 | 6.1 | 5.0 | 7.1 | 14 May 2025 | 17 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | E | 8 | 6.1 | 2.8 | 8.3 | 9 Sep 2025 | 21 May 2026 |
| Xingruida XDRCASE #VI-2026-0898 | C | 6 | 6.0 | 4.0 | 8.4 | 17 Jul 2025 | 19 May 2026 |
| LiliPeptideCASE #VI-2026-0695 | E | 10 | 5.9 | 0.0 | 10.0 | 17 Nov 2025 | 21 May 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 8 | 5.8 | 0.0 | 9.9 | 11 Aug 2025 | 23 May 2026 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 5.8 | 5.8 | 5.8 | 24 Jul 2025 | 24 Jul 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | E | 11 | 5.7 | 2.2 | 8.0 | 4 Aug 2025 | 21 May 2026 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | E | 6 | 5.7 | 1.4 | 8.0 | 13 Jun 2025 | 20 May 2026 |
| OupeptideCASE #VI-2026-0435 | E | 10 | 5.5 | 0.8 | 8.0 | 10 Aug 2025 | 24 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 5.5 | 5.5 | 5.5 | 27 Jun 2025 | 27 Jun 2025 |
| Peptide-SCASE #VI-2026-0111 | D | 7 | 5.4 | 3.5 | 8.0 | 13 Jun 2025 | 15 Jan 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | E | 16 | 5.2 | 0.0 | 8.2 | 29 Jun 2025 | 21 May 2026 |
| SRY LabsCASE #VI-2026-0657 | E | 11 | 5.2 | 1.9 | 8.7 | 27 Jun 2025 | 17 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | E | 2 | 4.9 | 2.6 | 7.3 | 9 Oct 2025 | 21 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | E | 7 | 4.2 | 0.0 | 7.8 | 27 Jun 2025 | 25 May 2026 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 4.2 | 4.2 | 4.2 | 24 May 2026 | 24 May 2026 |
| Peptides 4 ResearchCASE #VI-2026-0511 | E | 4 | 4.0 | 3.4 | 4.6 | 7 May 2025 | 21 May 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 3.8 | 3.8 | 3.8 | 25 May 2026 | 25 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | E | 6 | 3.4 | 0.0 | 7.5 | 21 Oct 2025 | 24 May 2026 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 3.0 | 3.0 | 3.0 | 29 Jun 2025 | 29 Jun 2025 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 1.5 | 1.5 | 1.5 | 29 Jun 2025 | 29 Jun 2025 |
Open any subject to view the batch-level evidence for Tesamorelin alone.